Company Overview - Nuvation Bio is a commercial stage biotechnology company with several products in late-stage development [2] - The company’s lead commercial asset, IBTROZI (taletrectinib), is a next-generation ROS1 inhibitor approved for treating ROS1-positive non-small cell lung cancer [2] Product Pipeline - Safusidenib is a potentially best-in-class mutant IDH1 inhibitor currently in a pivotal study for treating both high-grade and low-grade gliomas [3] - NUV-868 is a BD2-selective BET inhibitor that has completed Phase I studies [3] - The company is also developing a novel drug-drug conjugate preclinical program aimed at providing targeted therapy to cancers [3] Financial Position - Nuvation Bio has a cash balance of approximately $589 million following a recent deal with Eisai [4] - The company anticipates a path to profitability without the need for further funding [4] - IBTROZI is being commercialized in partnership with Eisai, Innovent, and Nippon Kayaku [4]

Summary of Nuvation Bio Conference Call Company Overview - Nuvation Bio is a commercial stage biotechnology company with several late-stage products, including Iptrozi (talotrectinib), a ROS1 inhibitor for non-small cell lung cancer, and Safusidenib, a mutant IDH1 inhibitor for gliomas [2][20] Key Products and Developments Iptrozi (Talotrectinib) - Approved in June for treating ROS1 positive non-small cell lung cancer - Achieved 432 new patient starts since launch, reflecting a 6X faster launch than competitors [5] - Sales increased from 204 new patient starts in Q3 to 216 in Q4, a 6% quarter-over-quarter increase [4] - Market leader in ROS1 TKIs with 90% of lives covered to label [5] - Response rate of 89% and median duration of response (DOR) of 50 months, which is elite among oncology agents [8][9] - Theoretical market opportunity in the U.S. could approach $5 billion with RNA testing becoming the standard [18] Safusidenib - A mutant IDH1 inhibitor for gliomas, with significant commercial potential due to long survival rates in patients [21] - Currently in pivotal studies, showing promising response rates compared to the only approved drug, vorasidenib [26] - Anticipated to enroll 300 patients in pivotal studies, with readouts expected by 2029 [27] BD2-Selective BET Inhibitor - Most selective BET inhibitor in development, having completed phase 1 studies [31] Drug-Drug Conjugate (DDC) Platform - Innovative approach using two small molecules for targeted cancer therapy, currently in optimization phase [32] Financial Overview - Current cash balance of approximately $589 million, expected to increase to $620 million with upcoming milestones [3][33] - Revenue stacking potential from Iptrozi could lead to significant long-term revenue growth [17] Market Dynamics - Shift in NCCN guidelines contraindicating immuno-oncology (IO) for ROS1 lung cancer, favoring ROS1 agents like Iptrozi [19] - Increased incidence of ROS1 fusions detected through RNA testing, potentially expanding the patient pool and market opportunity [18] Clinical Data and Efficacy - Iptrozi shows superior efficacy compared to first-generation TKIs, with a lower discontinuation rate of 6.5% [11][12] - Safusidenib demonstrates lower progression rates and higher response rates compared to vorasidenib [25][26] Strategic Priorities - Focus on continuing the successful launch of Iptrozi and increasing awareness of next-generation sequencing (NGS) testing in the community [36][37] - Rapid enrollment in pivotal studies for Safusidenib, targeting high-grade and high-risk low-grade gliomas [39] Conclusion - Nuvation Bio is positioned for significant growth with its innovative therapies and strong market presence, particularly in the ROS1 positive lung cancer and glioma spaces, supported by robust clinical data and strategic financial management [34][35]